Gapping up
In reaction to earnings/guidance:
- TRQ +6.4%, LOGI +3.7%, HAL +2.8%, GS +2.8%, FSM +2.1%, KFRC +1.9%, TROX +1.3%, SMTS +1.1%, CMA +0.7%
M&A news:
- COHR +34.3% (Lumentum (LITE) and Coherent (COHR) to merge)
Other news:
- ACRS +68.9% (announced positive preliminary topline results from a 12-week, Phase 2a trial of ATI-450 in subjects with moderate to severe rheumatoid arthritis)
- TRXC +36.7% (receives CE mark for machine vision system in robotic surgery)
- GRTS +27.7% (advances second generation COVID-19 vaccine "coral" program with support from NIAID; program has potential to protect against mutant variants of SARS-CoV-2)
- TSHA +17.9% (receives rare pediatric disease and orphan drug designations for TSHA-105 for the treatment of epilepsy caused by SLC13A5 Deficiency)
- VRCA +13.9% (present data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials evaluating the safety and efficacy of VP-102 in molluscum contagiosum (molluscum) in specific body regions at each visit)
- DTIL +11.2% (FDA has accepted the IND application for PBCAR19B for patients with relapsed/refractory (R/R) Non-Hodgkin Lymphoma)
- ARAY +9.7% (announces that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8% had local disease control seven years after receiving once-daily accelerated partial breast irradiation delivered with the TomoTherapy System)
- SSP +9.6% (Berkshire Hathaway (BRK.B) reports 24.9% passive stake in 13G filing)
- MCRB +8.1% (will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection)
- CYAD +7.9% (Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101)
- MTCR +7.1% (announces FDA fast track designation for MET642 as a treatment of NASH)
- GRFS +6.8% (begins clinical trial of a new treatment that would provide immediate immunity against COVID-19)
- WU +6.2% (Western Union and Walmart (WMT) enter agreement to offer western union money transfers at Walmart)
- MRUS +5.5% (Eli Lilly and Merus NV (MRUS) announce collaboration to discover novel T-Cell re-directing bispecific antibodies)
- CTSO +4.9% (announces approval of CytoSorb in Korea in collaboration with partner Fresenius Medical Care)
- BEAM +4.4% (announces $260 million common stock investment from multiple investors)
- SKYW +4% (receives half of $233 mln in PSP funds)
- ALLT +3.8% (Tier-1 Telecom service provider in Europe selects Allot HomeSecure and BusinessSecure to provide cyber-protection to consumers and SMbs)
- CRSP +3.6% (files for $600 mln common stock offering)
- PRLB +3.3% (entered into a definitive agreement to acquire 3D Hubs)
- SOL +3.2% (files for $250 mln mixed securities shelf offering)
- AZN +2.7% (ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer)
- EQNR +2.6% (has been awarded 17 new production licenses by Norway's Ministry of Petroleum and Energy)
- APT +2% (Biden says he will sign executive order requiring masks on federal property, planes trains, wherever he has authority to do so)
- PAAS +1.9% (reports FY20 silver production; provides FY21 outlook) GM +1.8% (to invest nearly $800 million to convert CAMI into Canada's first large-scale commercial electric vehicle manufacturing plant)
- LLY +1.8% (Eli Lilly and Merus NV (MRUS) announce collaboration to discover novel T-Cell re-directing bispecific antibodies)
- AGIO +1.7% (Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO)
- ORTX +1.7% (to extend the company's commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN)
Analyst comments:
- BLDP +8.4% (initiated with an Outperform at BMO Capital Markets)
- ETM +7.5% (upgraded to Overweight from Equal Weight at Wells Fargo)
- CLF +4.2% (upgraded to Outperform from Neutral at Exane BNP Paribas)
- PAGS +3.3% (upgraded to Buy from Neutral at Goldman)
- DRI +3.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SNDR +3.2% (upgraded to Outperform from Neutral at Credit Suisse)
- ITW +2.9% (upgraded to Neutral from Sell at Goldman)
- LI +2.5% (initiated with a Buy at Jefferies)
- EMR +2.2% (upgraded to Buy from Neutral at Goldman)
- ROKU +2.2% (initiated with an Overweight at JP Morgan)
- GILD +2.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- FB +2% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- AXP +1.9% (upgraded to Overweight from Underweight at JP Morgan)
- NDAQ +1.4% (upgraded to Buy from Neutral at UBS)